JAK Inhibitors in Inflammatory Bowel Disease: Mechanism, Indications, and Safety Considerations
Muhammad Waqas, Ex Resident Pharmacist at Shifa International Hospitals Limited, shared on LinkedIn:
“๐๐๐ ๐๐ป๐ต๐ถ๐ฏ๐ถ๐๐ผ๐ฟ๐ ๐ถ๐ป ๐๐๐
1. Mechanism of Action: Janus kinase (JAK) inhibitors block intracellular JAK-STAT signaling,reduces cytokine-driven inflammation. They are oral small molecules (unlike biologics) and act on multiple cytokine pathways.
๐ฎ. ๐๐ฝ๐ฝ๐ฟ๐ผ๐๐ฒ๐ฑ ๐๐๐ ๐๐ป๐ต๐ถ๐ฏ๐ถ๐๐ผ๐ฟ๐
Tofacitinib: Oral, non-selective JAK1/3 inhibitor
Upadacitinib: Oral, selective JAK1 inhibitor
Filgotinib Oral, selective JAK1 inhibitor
Peficitinib Investigational / clinical trials JAK1/3 inhibitor
3. Indications / Patient Selection
โข Moderate-to-severe UC failing:
โข Corticosteroids
โข Immunomodulators (azathioprine, 6-MP)
โข Biologics (biologic-refractory disease.)
โข Useful for patients preferring oral therapy
๐ฐ. ๐๐ผ๐๐ถ๐ป๐ด (๐ฒ๐
๐ฎ๐บ๐ฝ๐น๐ฒ)
โข ๐ง๐ผ๐ณ๐ฎ๐ฐ๐ถ๐๐ถ๐ป๐ถ๐ฏ:
โข ๐๐ป๐ฑ๐๐ฐ๐๐ถ๐ผ๐ป: ๐ญ๐ฌ ๐บ๐ด ๐ผ๐ฟ๐ฎ๐น๐น๐ ๐๐๐ ๐ณ๐ผ๐ฟ ๐ด ๐๐ฒ๐ฒ๐ธ๐
โข ๐ ๐ฎ๐ถ๐ป๐๐ฒ๐ป๐ฎ๐ป๐ฐ๐ฒ: ๐ฑโ๐ญ๐ฌ ๐บ๐ด ๐๐๐ (๐ฏ๐ฎ๐๐ฒ๐ฑ ๐ผ๐ป ๐ฟ๐ฒ๐๐ฝ๐ผ๐ป๐๐ฒ)
โข ๐จ๐ฝ๐ฎ๐ฑ๐ฎ๐ฐ๐ถ๐๐ถ๐ป๐ถ๐ฏ:
โข ๐๐ป๐ฑ๐๐ฐ๐๐ถ๐ผ๐ป: ๐ฐ๐ฑ ๐บ๐ด ๐ฑ๐ฎ๐ถ๐น๐
โข ๐ ๐ฎ๐ถ๐ป๐๐ฒ๐ป๐ฎ๐ป๐ฐ๐ฒ: ๐ญ๐ฑโ๐ฏ๐ฌ ๐บ๐ด ๐ฑ๐ฎ๐ถ๐น๐
๐ฑ. ๐๐ฑ๐๐ฒ๐ฟ๐๐ฒ ๐๐ณ๐ณ๐ฒ๐ฐ๐๐ / ๐ฆ๐ฎ๐ณ๐ฒ๐๐
โข Infections: Herpes zoster, serious bacterial/fungal infections
โข Thrombosis risk: Deep vein thrombosis, pulmonary embolism (especially at higher doses or risk factors)
โข Lipid abnormalities: โ LDL, โ HDL
โข Hematologic: Anemia, leukopenia, lymphopenia
โข Other: GI perforation (rare), elevated liver enzymes
๐ฒ. ๐ ๐ผ๐ป๐ถ๐๐ผ๐ฟ๐ถ๐ป๐ด
โข Baseline: CBC, LFTs, lipid profile, TB and hepatitis screening
โข Ongoing: CBC, LFTs, lipid profile periodically; monitor for infections”
Read more on Hemostasis Today.
-
Jun 21, 2026, 14:38Christina (Tina) P: Staying Safe on Anticoagulation Therapy in Antiphospholipid Syndrome
-
Jun 21, 2026, 14:32Moeen Hoseini: The Sex-Specific Associations Between Inflammatory Biomarkers and Vascular Events
-
Jun 21, 2026, 14:23Orton Lungu: Navigating High-Risk Pregnancy in Women Living With Sickle Cell Disease
-
Jun 21, 2026, 14:11Alexandre Kauskot: A Guide to Parisโs Best Riverside Spots for ISTH 2026 Attendees
-
Jun 21, 2026, 14:10Avidesh Panday: Data-Driven Stroke Care Transformation at EWMSC
-
Jun 21, 2026, 13:41Emmanuel J. Favaloro: Honored to Receive the ISLH Wallace H. Coulter Distinguished Lecture Award
-
Jun 21, 2026, 11:50Khalil Ahmad: The Incredible Journey of a Red Blood Cell – A Lifelong Mission of Oxygen Delivery
-
Jun 21, 2026, 08:44Patient Experience Sheds Light on Complexities of Antithrombotic Care in APS – APS Foundation of America
-
Jun 21, 2026, 08:04Phil Ambery: Next-Generation Endothelin Therapeutics Renew Interest in a Proven Pathway